Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab +/- Ipilimumab and RT in Resectable Sarcoma
NCT03307616Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2017
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in undifferentiated pleomorphic sarcoma (UPS), dedifferentiated liposarcoma (DDL), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2017; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
undifferentiated pleomorphic sarcoma (UPS)dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT03307616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03307616.